LeMaitre Vascular (NASDAQ:LMAT) Upgraded to Buy at StockNews.com

StockNews.com upgraded shares of LeMaitre Vascular (NASDAQ:LMAT) from a hold rating to a buy rating in a research report released on Monday.

Several other equities analysts have also recently weighed in on the company. Barrington Research lifted their price target on LeMaitre Vascular from $79.00 to $92.00 and gave the company an outperform rating in a research report on Friday, August 2nd. Lake Street Capital started coverage on shares of LeMaitre Vascular in a report on Friday, August 2nd. They issued a buy rating and a $105.00 price target on the stock. Roth Capital upgraded shares of LeMaitre Vascular to a strong-buy rating in a research note on Friday, May 31st. Roth Mkm reaffirmed a buy rating and issued a $100.00 price target on shares of LeMaitre Vascular in a report on Friday, May 31st. Finally, JMP Securities raised their price target on LeMaitre Vascular from $72.00 to $77.00 and gave the company a market outperform rating in a report on Friday, May 3rd. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of Buy and a consensus target price of $86.50.

LeMaitre Vascular Price Performance

NASDAQ:LMAT opened at $83.59 on Monday. The company has a market capitalization of $1.88 billion, a P/E ratio of 55.36, a P/E/G ratio of 2.63 and a beta of 0.89. LeMaitre Vascular has a 1 year low of $44.27 and a 1 year high of $91.76. The business has a fifty day simple moving average of $83.28 and a two-hundred day simple moving average of $73.22.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.63%. The firm had revenue of $55.85 million during the quarter, compared to analyst estimates of $54.98 million. During the same quarter last year, the business earned $0.37 earnings per share. The company’s quarterly revenue was up 11.4% on a year-over-year basis. As a group, analysts anticipate that LeMaitre Vascular will post 1.77 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, August 29th. Investors of record on Thursday, August 15th will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.77%. The ex-dividend date of this dividend is Thursday, August 15th. LeMaitre Vascular’s dividend payout ratio is currently 42.38%.

Insider Buying and Selling at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 27,030 shares of the stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $86.27, for a total value of $2,331,878.10. Following the completion of the transaction, the chief executive officer now owns 1,958,328 shares of the company’s stock, valued at approximately $168,944,956.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO George W. Lemaitre sold 27,030 shares of the firm’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the completion of the transaction, the chief executive officer now owns 1,958,328 shares of the company’s stock, valued at approximately $168,944,956.56. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO George W. Lemaitre sold 12,976 shares of the stock in a transaction on Friday, July 12th. The shares were sold at an average price of $86.07, for a total value of $1,116,844.32. Following the sale, the chief executive officer now owns 1,985,358 shares in the company, valued at $170,879,763.06. The disclosure for this sale can be found here. In the last three months, insiders have sold 43,251 shares of company stock valued at $3,714,994. 10.79% of the stock is currently owned by corporate insiders.

Institutional Trading of LeMaitre Vascular

Large investors have recently added to or reduced their stakes in the business. YHB Investment Advisors Inc. purchased a new stake in LeMaitre Vascular in the first quarter worth about $36,000. GAMMA Investing LLC increased its stake in LeMaitre Vascular by 57.0% in the 2nd quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after buying an additional 199 shares in the last quarter. SRS Capital Advisors Inc. raised its holdings in LeMaitre Vascular by 325.5% during the fourth quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock valued at $39,000 after acquiring an additional 524 shares during the period. West Oak Capital LLC purchased a new stake in shares of LeMaitre Vascular during the second quarter worth about $58,000. Finally, nVerses Capital LLC raised its stake in LeMaitre Vascular by 33.3% during the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock valued at $66,000 after purchasing an additional 200 shares during the period. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.